Workboat Indexes

Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

401.71 +4.46 (+1.12%)

Streaming Delayed Price Updated: 12:37 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates ↗

April 01, 2022

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with...

Via Benzinga

Alnylam to Webcast Presentation at Stifel 2022 CNS Days

March 22, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

World Markets News For Friday ↗

March 18, 2022

Buoyant global markets are closing the week and one good performer, Vir Biotech, today gained an impressive 6.09%.

Via Talk Markets

Earnings Scheduled For February 10, 2022 ↗

February 10, 2022

Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million.

Via Benzinga

Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters ↗

March 18, 2022

Canada-based Acuitas Therapeutics Inc has sued Arbutus Biopharma Corporation (NASDAQ: ABUS) in Manhattan federal court, seeking to head off claims that the vaccine infringes Arbutus' patents,

Via Benzinga

Alnylam Hits Pfizer, Moderna With Patent Infringement Suits ↗

March 17, 2022

Via Benzinga

Alnylam Pharmaceuticals Files Patent Infringement Suits against Pfizer and Moderna

March 17, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Issues 2021 Corporate Responsibility Report

March 16, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

What 8 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗

March 01, 2022

Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022 ↗

March 01, 2022

Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,...

Via Benzinga

Alnylam Debuts New Documentary, Two of Me: Living with Porphyria, to Help Shorten Time to Diagnosis for Acute Hepatic Porphyria (AHP)

February 28, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Looking Into Alnylam Pharmaceuticals's Return On Capital Employed ↗

February 11, 2022

Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q4 sales of $258.54 million. Earnings fell to a loss of $258.46 million, resulting in a 26.38% decrease from last quarter.

Via Benzinga

Expert Ratings For Alnylam Pharmaceuticals ↗

February 11, 2022

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

Alnylam Clocks 76% Increase In Q4 Product Sales, Expects FY22 Product Sales Of Up To $1B ↗

February 10, 2022

Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY)

Via Benzinga

The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly ↗

February 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Alnylam Pharmaceuticals: Q4 Earnings Insights ↗

February 10, 2022

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q4 earnings results on Thursday, February 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period Activity

February 10, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentation at 11th Annual SVB Leerink Global Healthcare Conference

February 08, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2022 ↗

February 03, 2022

Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago...

Via Benzinga

The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More ↗

February 06, 2022

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...

Via Benzinga

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial Results

January 24, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

A Bearish Sign Appears On Alnylam Pharmaceuticals's Chart ↗

January 21, 2022

If history is any guide, there may be trouble ahead for shares of Alnylam Pharmaceuticals (NASDAQ:ALNY). A so-called "death cross" has formed on its chart and, not surprisingly,...

Via Benzinga

Alnylam' Reveals Detailed 18-Month Data From Vutrisiran Trial In Inherited Disease ↗

January 21, 2022

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) has announced detailed data from HELIOS-A Phase 3 study of vutrisiran at 18 months in patients with transthyretin-...

Via Benzinga

The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective ↗

January 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kura Announces Lifting Of Clinical Hold On Phase 1 Blood Cancer Study Kura...

Via Benzinga

Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy

January 21, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

What 10 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗

January 20, 2022

Over the past 3 months, 10 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:

Via Benzinga

The Week Ahead In Biotech (Jan. 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week ↗

January 16, 2022

Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Here are the key catalysts...

Via Talk Markets

The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week ↗

January 16, 2022

Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Swiss...

Via Benzinga

The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks ↗

January 13, 2022

Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year?

Via Investor's Business Daily

Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting

January 14, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Workboat Indexes

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

Coast Guard awards Arctic Security Cutter contracts

Fire damages Portland’s historic waterfront

New England governors, grid operators warn on latest Trump wind shutdown

Stonepeak to buy majority stake in Castrol